Scarica l'app Stockscreener
1.48
6.33%
-0.10
Pre-mercato:
1.44
-0.04
-2.70%
Precedente Chiudi:
$1.58
Aprire:
$1.48
Volume 24 ore:
227.75K
Relative Volume:
0.20
Capitalizzazione di mercato:
$2.77M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-12.43%
1M Prestazione:
-45.39%
6M Prestazione:
-67.40%
1 anno Prestazione:
-89.96%
Intervallo 1D:
$1.46
$1.5499
Intervallo di 1 settimana:
$1.45
$1.82
Portata 52W:
$1.41
$62.72
Psyence Biomedical Ltd Stock (PBM) Company Profile
Nome
Psyence Biomedical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PBM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
1.48 | 2.96M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Psyence Biomedical Ltd Borsa (PBM) Ultime notizie
Psyence Biomedical Ltd. (PBM) -5.7% in After-hours: Despite No Clear Catalyst - Stocks Telegraph
Psyence BioMed Advances Phase IIb Clinical Trial and Expands Board - MSN
Check out these key findings about Psyence Biomedical Ltd (PBM) - setenews.com
Rapid Surge: Psyence Biomedical’s Unexpected Stock Movement - StocksToTrade
Psyence BioMed (PBM) Stock: Drives Forward with Phase IIb Trial and Unique Longevity Science Position - parameter.io
Psyence Biomedical Ltd. (PBM) Stock: Drops, But Company Pushes Forward with Groundbreaking Psychedelic Therapies - parameter.io
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science - Asianet Newsable
Psyence BioMed (Nasdaq: PBM) advances Phase IIb trial, ibogaine supply leadership - Stock Titan
Bull Run: Why Psyence Biomedical Ltd stock appeals to dividend seekersTrade Performance Summary & Long-Term Growth Portfolio Plans - moha.gov.vn
How Psyence Biomedical Ltd. Equity Warrant stock benefits from global expansionJuly 2025 Market Mood & Reliable Entry Point Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock remain a Wall Street favoriteWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock sustain high P E ratiosAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
Is Psyence Biomedical Ltd. stock attractive for growth ETFsPortfolio Risk Report & Reliable Entry Point Trade Alerts - Newser
Price to earnings ratio of Psyence Biomedical Ltd. Warrant 20242028 on Psyence Biomedical – NASDAQ:PBMWW - TradingView
Psyence Biomedical (PBM) Stock Analysis Report | Financials & Insights - Benzinga
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell? - Defense World
Psyence Biomedical Ltd. (PBM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Psyence Biomedical : The Future of Human Longevity Will Be Transformational – And Nature May Hold the Key - marketscreener.com
How geopolitical tensions affect Psyence Biomedical Ltd. stockWeekly Trade Report & Safe Capital Growth Tips - BỘ NỘI VỤ
Psyence BioMed leads longevity research on psilocybin - Longevity.Technology
How Psyence Biomedical Ltd. stock performs in weak economyJuly 2025 Spike Watch & Reliable Breakout Forecasts - BỘ NỘI VỤ
Its Stock Has Paid Off Big Time For Psyence Biomedical Ltd - Setenews
Breakout Move: Why Psyence Biomedical Ltd. Equity Warrant stock is popular among millennialsEntry Point & Safe Capital Growth Stock Tips - moha.gov.vn
Psyence Biomedical launches psilocybin longevity research program By Investing.com - Investing.com Nigeria
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program - Asianet Newsable
Psyence Biomedical launches psilocybin longevity research program - Investing.com
Psyence BioMed Expands Ibogaine Operations in Africa with Strategic Investment - MSN
Psyence Biomedical Ltd. (PBM) -13.37% in Normal Trading: Decline Amid Recent Breakthrough Announcement - Stocks Telegraph
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
[6-K] PSYENCE BIOMEDICAL LTD. Current Report (Foreign Issuer) | PBM SEC FilingForm 6-K - Stock Titan
Psyence Biomedical Reports Strong Financial Growth in Latest Interim Results - MSN
Will Psyence Biomedical Ltd. stock rally after Fed decisionsPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Is Psyence Biomedical Ltd. stock in correction or buying zoneWeekly Trading Summary & Weekly Setup with ROI Potential - newser.com
The time has not yet come to remove your chips from the table: Psyence Biomedical Ltd (PBM) - Setenews
How Psyence Biomedical Ltd. Equity Warrant stock reacts to job market dataJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Psyence BioMed secures sustainable iboga supply for clinical research By Investing.com - Investing.com Nigeria
[424B3] PSYENCE BIOMEDICAL LTD. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Is PBM’s Market Boost a Fleeting Mirage? - StocksToTrade
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025 - ts2.tech
Is It Time to Buy PBM Stock? - timothysykes.com
Psyence BioMed secures sustainable iboga supply for clinical research - Investing.com
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets - The Manila Times
Psyence BioMed Reaches Major Breakthrough in - GlobeNewswire
Institutional scanner results for Psyence Biomedical Ltd. Equity WarrantMarket Growth Report & Reliable Price Breakout Alerts - newser.com
Psyence Biomedical Ltd Azioni (PBM) Dati Finanziari
Non sono disponibili dati finanziari per Psyence Biomedical Ltd (PBM). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):